Correction to: Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

被引：0
|
作者：
Taylor M. Patek
Chengwen Teng
Kaitlin E. Kennedy
Carlos A. Alvarez
Christopher R. Frei
机构：
[1] The University of Texas at Austin,Pharmacotherapy Division, College of Pharmacy
[2] The University of Texas Health Science Center at San Antonio,Pharmacotherapy Education and Research Center, Long School of Medicine
[3] Texas Tech University Health Sciences Center,Division of Clinical/Translational Research, Hodge School of Pharmacy
[4] South Texas Veterans Health Care System,undefined
[5] University Health System,undefined
来源：
Drug Safety | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In the original publication of the article, the second sentence in the figure 2 caption should read as below:
引用
下载
收藏
页码：825 / 825
相关论文
共 50 条
  • [41] Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
    Sato, Kenichiro
    Mano, Tatsuo
    Iwata, Atsushi
    Toda, Tatsushi
    BIOSCIENCE TRENDS, 2020, 14 (02) : 139 - 143
  • [42] A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS)
    Min Huang
    Peng Li
    Archives of Dermatological Research, 317 (1)
  • [43] Pediatric drug-induced anaphylaxis reports in the FDA Adverse Event Reporting System (FAERS)
    Brameli, Anna
    Yuan, Irene H.
    Phillips, Elizabeth J.
    Stone Jr, Cosby A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (09):
  • [44] Evaluation of Ticagrelor Bleeding Adverse Event Reports Compared to Clopidogrel in the FDA Adverse Events Reporting System (FAERS)
    Fahmy, Ahmed I.
    Mekkawy, Mohamed A.
    Abou-Ali, Adel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 186 - 186
  • [45] Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)
    Shi, Alan
    Nguyen, Harold
    Kuo, C. Benson
    Beringer, Paul M.
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (03) : 566 - 572
  • [46] Reports of adverse events related with second generation antipsychotics in children in the FDA adverse event reporting system (FAERS)
    Zapata, Lorenzo Villa
    Bibbs, Janese
    Crapps, Mariah
    Lumbreras, Ainhoa Gomez
    Malone, Daniel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 579 - 580
  • [47] A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)
    Tang, Linlin
    Sun, Cuicui
    Liu, Wenshan
    Wu, Haiyan
    Ding, Chuanhua
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [48] Pharmacovigilance study of the association between dipeptidyl peptidase–4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS)
    Katsuhiro Ohyama
    Junichiro Shindo
    Tomohiro Takahashi
    Hironori Takeuchi
    Yusuke Hori
    Scientific Reports, 12
  • [49] Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
    Teng, Chengwen
    Walter, Elizabeth A.
    Gaspar, Daryl Kevin S.
    Obodozie-Ofoegbu, Obiageri O.
    Frei, Christopher R.
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2019, 16 (07): : 1018 - 1022
  • [50] Voriconazole-induced central nervous system toxicity: a pharmacovigilance study based on FDA adverse event reporting system (FAERS) database
    Yun, Juping
    Wang, Zihe
    Liu, Wei
    EXPERT OPINION ON DRUG SAFETY, 2024,
12345